Evidence map›Paper›PMID 34750269›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Rational prioritization strategy allows the design of macrolide derivatives that overcome antibiotic resistance.

Gerhard König, Pandian Sokkar, Niclas Pryk, Sascha Heinrich, David Möller, Giuseppe Cimicata, Donna Matzov, Pascal Dietze, Walter Thiel, Anat Bashan and 5 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Elucidating Antibiotic Permeation through theJournal of chemical information and modeling · 2024
    Article
  5. Current State-of-the-Art Toward Chemoenzymatic Synthesis of Polyketide Natural Products.Chembiochem : a European journal of chemical biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gerhard KönigDepartment of Theory, Max-Planck-Institut für Kohlenforschung, 45470 Mülheim an der Ruhr, Germany.
Pandian SokkarDepartment of Theory, Max-Planck-Institut für Kohlenforschung, 45470 Mülheim an der Ruhr, Germany.ORCID 0000-0002-6692-7066
Niclas PrykFakultät für Chemie und Biochemie, Ruhr-Universität Bochum, 44801 Bochum, Germany.
Sascha HeinrichFakultät für Chemie und Biochemie, Ruhr-Universität Bochum, 44801 Bochum, Germany.ORCID 0000-0003-2193-5422
David MöllerFakultät für Chemie und Biochemie, Ruhr-Universität Bochum, 44801 Bochum, Germany.
Giuseppe CimicataDepartment of Chemical and Structural Biology, Weizmann Institute, Rehovot 76100 001, Israel.
Donna MatzovDepartment of Chemical and Structural Biology, Weizmann Institute, Rehovot 76100 001, Israel.
Pascal DietzeFakultät für Biologie und Biotechnologie, Ruhr-Universität Bochum, 44801 Bochum, Germany.
Walter ThielDepartment of Theory, Max-Planck-Institut für Kohlenforschung, 45470 Mülheim an der Ruhr, Germany.
Anat BashanDepartment of Chemical and Structural Biology, Weizmann Institute, Rehovot 76100 001, Israel.
Julia Elisabeth BandowFakultät für Biologie und Biotechnologie, Ruhr-Universität Bochum, 44801 Bochum, Germany.ORCID 0000-0003-4100-8829
Johannes ZueggCommunity for Open Antimicrobial Drug Discovery, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Ada YonathDepartment of Chemical and Structural Biology, Weizmann Institute, Rehovot 76100 001, Israel; ada.yonath@weizmann.ac.il frank.schulz@ruhr-uni-bochum.de elsa.sanchez-garcia@uni-due.de.
Frank SchulzFakultät für Chemie und Biochemie, Ruhr-Universität Bochum, 44801 Bochum, Germany; ada.yonath@weizmann.ac.il frank.schulz@ruhr-uni-bochum.de elsa.sanchez-garcia@uni-due.de.ORCID 0000-0003-3946-7137
Elsa Sanchez-GarciaDepartment of Theory, Max-Planck-Institut für Kohlenforschung, 45470 Mülheim an der Ruhr, Germany; ada.yonath@weizmann.ac.il frank.schulz@ruhr-uni-bochum.de elsa.sanchez-garcia@uni-due.de.ORCID 0000-0002-9211-5803

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance is a major threat to global health; this problem can be addressed by the development of new antibacterial agents to keep pace with the evolutionary adaptation of pathogens. Computational approaches are essential tools to this end since their application enables fast and early strategical decisions in the drug development process. We present a rational design approach, in which acylide antibiotics were screened based on computational predictions of solubility, membrane permeability, and binding affinity toward the ribosome. To assess our design strategy, we tested all candidates for in vitro inhibitory activity and then evaluated them in vivo with several antibiotic-resistant strains to determine minimal inhibitory concentrations. The predicted best candidate is synthetically more accessible, exhibits higher solubility and binding affinity to the ribosome, and is up to 56 times more active against resistant pathogens than telithromycin. Notably, the best compounds designed by us show activity, especially when combined with the membrane-weakening drug colistin, against

Indexed as

Anti-Bacterial AgentsBacteriaColistinDrug Resistance, Multiple, BacterialMacrolidesMicrobial Sensitivity TestsAnti-Bacterial AgentsColistinMacrolidesantibioticsfree energyQM/MMresistanceribosome

Identifiers

PMID34750269
PMCPMC8609559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.